or an affiliate within the next three months. William Blair or an affiliate expects to receive or intends to seek compensation for investment banking services from Tempest Therapeutics, Inc. William Blair or an affiliate is a market maker in the security of Tempest Therapeutics, Inc. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments, or strategies to particular clients. This report is not intended to provide personal investment advice. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. William Blair or an affiliate does and seeks to do business with companies covered in its research reports. *Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.* We provide advisory services, strategies, and solutions to meet our clients’ evolving needs. William Blair is the premier global boutique with expertise in investment banking, investment management, and private wealth management. We believe the addition of TPST-1120 on top of standard of care in the first-line HCC setting provides a promising opportunity to jump straight to frontline treatment, although initial efficacy data is not expected until 2023.”
Tempest therapeutics plus#
Initial Phase I data showed a deep partial response in combination with Opdivo in a renal cell carcinoma patient previously treated with Opdivo plus Yervoy. He added, “Tempest is also trialing the first-in-clinic PPARα inhibitor TPST-1120 in a Phase I/Ib study as both monotherapy and in combination with Opdivo, as well as in a randomized Phase Ib/II study in first-line hepatocellular carcinoma (HCC) in collaboration with Roche. Tempest is evaluating TPST-1495 in a monotherapy dose-finding study with plans to open a PD-1 combination study and expansion in specific cohorts, including PIK3CA-mutated tumors, in coming months.” “This provides strong rationale for evaluating TPST-1495, a dual antagonist of two key immuno-suppressive PGE2 receptors, EP2 and EP4, in these tumor types. “We believe there is compelling translational and clinical data showing PIK3CA-mutated tumors use PGE2-mediated immune suppression, and survival benefits have been seen across numerous clinical studies by blocking PGE2 production with NSAIDs, particularly in PIK3CA-mutated colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (SCCHN),” he said. (TPST $13.96), which is developing a pipeline of small-molecule therapies for novel disease targets, including TPST-1495, a dual EP2/EP4 antagonist, to treat prostaglandin-driven cancers.Īnalyst Matt Phipps noted the potential of Tempest’s pipeline of first-in-class targeted oncology programs, TPST-1495 and TPST-1120.
is an Equal Opportunity Employer and all applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.William Blair initiated research coverage of Tempest Therapeutics, Inc. Consequently, we strive to adhere to our Guiding Principles, which provide the framework for a work environment that is constructive, productive and satisfying. The Tempest team believes in establishing a culture, as opposed to letting it happen. People of color and those who are part of underrepresented groups in the biotech industry are encouraged to apply for open positions. We have established and plan to nurture a culture that is inclusive and embodies the company’s Guiding Principles. Although it’s nice to have, hope isn’t a strategy for success, so we seek colleagues across all functions who can hit the ground running and share our passion for patients, science, and drug development. The people at Tempest have come together to discover and develop novel therapeutics to treat cancer – a challenging goal, but worth it.
We are an experienced team with diverse backgrounds working to make a difference for cancer patients.
0 kommentar(er)
